12
views
0
recommends
+1 Recommend
2 collections
    0
    shares

      Call for Papers: Digital Diagnostic Techniques

      Submit here before November 30, 2024

      About Pathobiology: 3.5 Impact Factor I 8.5 CiteScore I 1.088 Scimago Journal & Country Rank (SJR)

      Call for Papers: Supportive Care - Essential for Modern Oncology

      Submit here before December 31, 2024

      About Oncology Research and Treatment: 2.0 Impact Factor I 3.2 CiteScore I 0.521 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Remitting Seronegative Symmetrical Synovitis with Pitting Edema: A Case Report of an Immune-Related Adverse Event following Surgery

      case-report

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Immune checkpoint inhibitors (ICIs) have emerged as a novel class of anti-neoplastic agent in oncology. Their integration into practice has been accompanied by “immune-related adverse events” (irAEs) wherein off-target immune responses damage healthy tissues. Severe irAEs can cause irreversible organ dysfunction and death. Despite this, little is known about factors which predispose certain patients to develop irAEs or which precipitate their onset. Here, we report a case of a patient with melanoma who completed adjuvant immunotherapy, underwent elective hip replacement, and developed a rare rheumatologic irAE (remitting seronegative symmetrical synovitis with pitting edema) post-operatively. Mechanistically, we hypothesize that surgery contributed to irAE pathogenesis as a sensitizing event in which self-antigens were presented to an immune system with diminished peripheral tolerance in the context of recent ICI administration. This case highlights a need for future correlative analyses, investigating whether iatrogenic interventions such as surgery might be associated with irAE development.

          Related collections

          Most cited references21

          • Record: found
          • Abstract: not found
          • Article: not found

          Immune-related adverse events of checkpoint inhibitors

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis

            Immunotherapy has determined unprecedented long-term responses in several hematological and solid tumors. In the MOUSEION-03 study, we conducted a meta-analysis to determine the possibility of achieving complete remissions (CR) with immunotherapy or immuno-oncology combinations in cancer patients.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy.

              To analyze immune-related adverse events (ir-AEs) in patients treated with radiation and immune checkpoint blockade.
                Bookmark

                Author and article information

                Journal
                Case Rep Oncol
                Case Rep Oncol
                CRO
                CRO
                Case Reports in Oncology
                S. Karger AG (Basel, Switzerland )
                1662-6575
                16 August 2023
                Jan-Dec 2023
                16 August 2023
                : 16
                : 1
                : 662-669
                Affiliations
                [a ]Department of Internal Medicine, University of Toronto, Toronto, ON, Canada
                [b ]Department of Medical Oncology and Haematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
                [c ]Department of Rheumatology, Trillium Health Partners, Mississauga, ON, Canada
                [d ]Department of Oncology, Juravinski Hospital and Cancer Centre, Hamilton Health Sciences, Hamilton, ON, Canada
                Author notes
                Correspondence to: Helena J. Janse van Rensburg, ellen.jansevanrensburg@ 123456mail.utoronto.ca
                Article
                532004
                10.1159/000532004
                10625819
                37933314
                217dfdc1-cd8c-4489-8151-e483591690f9
                © 2023 The Author(s). Published by S. Karger AG, Basel

                This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC) ( http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.

                History
                : 10 May 2023
                : 29 June 2023
                : 2023
                Page count
                Figures: 2, Tables: 1, References: 21, Pages: 8
                Funding
                This article received no external funding.
                Categories
                Case Report

                Oncology & Radiotherapy
                cancer,immunotherapy,immune checkpoint inhibitor,immune-related adverse event,rheumatology,remitting seronegative symmetrical synovitis with pitting edema,surgery,hip replacement,case report

                Comments

                Comment on this article